Needham & Company Raises Price Target on Infoblox (BLOX) Following 3Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Needham & Company Reiterate Buy Following Infoblox (BLOX) Analyst Day
June 2, 2015 7:53 AM EDTNeedham & Company reiterate a Buy rating and $33.00 price target on Infoblox (NYSE: BLOX) following an analyst meeting. Analyst Alex Henderson said that the presentations were unlikely to change the participants views.
Henderson commented, "BLOX hosted an analyst meeting in San Francisco... More
Infoblox (BLOX) PT Bumped to $30 at Piper Jaffray on 'Very Impressive' Q3
May 29, 2015 6:51 AM EDTPiper Jaffray analyst Troy Jensen reiterated an Overweight rating and boosted his price target on Infoblox (NYSE: BLOX) to $30.00 (from $28.00) following 'very impressive' Q3 results.
Jensen commented, "We were once again very impressed with BLOXs earnings results, and convinced the companys new... More
After-Hours Stock Movers 05/28: (HRTX) (STML) (GME) (BLOX) Higher; (DECK) (CLLS) Lower (more...)
May 28, 2015 5:51 PM EDTHeron Therapeutics, Inc. (Nasdaq: HRTX) 39.8% HIGHER; announced positive, top-line results from its recently completed Phase 3 MAGIC study. MAGIC evaluated the efficacy and safety of the Companys 5-HT3 receptor antagonist product candidate SUSTOL® (granisetron injection, extended release) as part of a three-drug regimen with the intravenous (IV) neurokinin-1 (NK1) receptor antagonist fosaprepitant and the IV corticosteroid dexamethasone for the prevention of delayed-onset chemotherapy-induced nausea and vomiting (CINV) following administration of highly emetogenic chemotherapy (HEC) agents.
Infoblox (BLOX) Tops Q3 EPS by 5c; Issues Solid Outlook
May 28, 2015 4:11 PM EDTInfoblox (NYSE: BLOX) reported Q3 EPS of $0.12, $0.05 better than the analyst estimate of $0.07. Revenue for the quarter came in at $78.1 million versus the consensus estimate of $75.25 million.
Infoblox sees Q4 2015 EPS of $0.09-$0.10, versus the consensus of $0.09. Infoblox sees Q4 2015 revenue of $79-81... More
Needham & Company Maintain a Buy Rating; Looking for Infoblox (BLOX) Fourth 'Beat and Raise'
May 28, 2015 8:08 AM EDTNeedham & Company maintain a Buy rating and $27 price target on Infoblox (NYSE: BLOX) leading up to its 3Q earnings release. Analyst Alex Henderson is expecting a strong quarter and a fourth "Beat and Raise". BLOX is scheduled to report its 3Q earnings after market close today,... More
Trading Radar for 5/28: Avago (AVGO), OmniVision (OVTI), GameStop (GME), Express (EXPR), Dangdang (DANG) Report
May 27, 2015 2:47 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
Abercrombie & Fitch (NYSE: ANF) - consensus loss $0.34
Agilysys, Inc. (Nasdaq: AGYS) - consensus loss $0.04
American Superconductor (Nasdaq: AMSC) - consensus loss $0.70
Auris Medical Holding (Nasdaq: EARS) - consensus loss $0.22
China Xiniya... More
